Long-Read Genome Closure, Resistome & Mobile Genetic Element Risk Profiling

Complete genomic context can change how an LBP strain is understood before IND-enabling work begins. Creative Biolabs helps teams close bacterial genomes, resolve plasmids, locate resistance and virulence-associated elements, and translate mobility findings into a practical strain safety and data-package readiness narrative for confident preclinical planning, partner diligence, and candidate prioritization.

Complete Genome Context for LBP Strain Safety Decisions

For live biotherapeutic product developers, short-read whole-genome sequencing can identify many genes but still leave critical safety questions unresolved. Plasmids may collapse into fragmented contigs, repeated insertion sequences can obscure genomic neighborhoods, and resistance genes, virulence-associated factors, prophages, integrative elements, or conjugation modules may be detected without clear evidence of where they sit or whether they are plausibly mobile.

These unresolved locations matter for IND-preparation teams, strain licensors, and LBP biotech groups that need to decide whether a candidate strain is ready for deeper preclinical investment. A gene located on a stable chromosomal region has a different safety interpretation than the same gene on an extrachromosomal plasmid, an integrative conjugative element, or a region dense with insertion sequences. Creative Biolabs provides Long-Read Genome Closure, Resistome & Mobile Genetic Element Risk Profiling service to turn fragmented strain genomics into a decision-ready safety data package.

Questions We Help Resolve

•Is the strain assembly closed enough to support genome-level safety interpretation?
•Are ARG, VF, prophage, insertion sequence, or conjugation markers chromosomal, plasmid-borne, or unresolved?
•Do mobile genetic element neighborhoods suggest a need for additional testing or strain selection review?
•What data gaps should be closed before licensing, partner diligence, or preclinical safety planning?

Long-Read Genome Closure and Resistome Risk Profiling Services

Our service is designed for teams that already have a candidate LBP strain or licensed isolate and need a clearer genomic basis for safety review, CMC readiness planning, and strain-selection decisions.

PacBio or ONT Genome Closure

We support long-read or hybrid assembly strategies to resolve circular chromosomes, plasmids, repeated regions, and structural arrangements that short-read assemblies may fragment. The goal is not only assembly contiguity, but usable genomic context for safety-relevant interpretation.

ARG, VF and MGE Annotation

We map antimicrobial resistance genes, virulence-associated genes, insertion sequences, transposons, integrons, prophage regions, conjugation modules, and plasmid replicons against curated analysis outputs, then interpret their genomic neighborhoods and risk implications.

Genome-Level Safety Report

We summarize sequence quality, closed-replicon structure, plasmid typing, gene location, mobility flags, and recommended follow-up assays in a concise report that can support internal review, licensing discussions, and preclinical data-package planning.

Genome Assemblyclosed chromosome and plasmid structure

Safety AnnotationARG, VF, prophage and MGE calls

Transferability Reviewplasmid, conjugation and insertion context

CMC Readinessgap map for strain safety package planning

Genome Safety Data Package Deliverables for LBP Programs

Each engagement is built around the decisions your team needs to make: continue development, compare candidate strains, prepare partner diligence material, or plan additional nonclinical studies.

Deliverable	What It Covers	Program Value
Closed Genome Assembly Summary	Replicon structure, circularity evidence, coverage review, assembly confidence, plasmid copy context, and unresolved regions if present.	Establishes whether the sequence foundation is strong enough for downstream safety interpretation.
Resistome and Virulence Annotation Matrix	ARG and VF calls with genomic coordinates, predicted function, identity thresholds, and location on chromosome, plasmid, or other replicons.	Supports transparent strain risk triage and reduces ambiguity in diligence discussions.
MGE and Plasmid Mobility Profile	Insertion sequences, transposons, integrase markers, prophage regions, conjugation genes, plasmid typing, and gene-neighborhood interpretation.	Helps distinguish simple gene presence from context that may indicate higher transfer concern.
Gap Assessment and Follow-Up Plan	Recommended confirmatory assays, antimicrobial susceptibility alignment, biological safety testing, stability checks, or strain-comparison studies.	Turns genomic findings into a practical preclinical CMC readiness roadmap.

Genome Closure and MGE Risk Assessment Workflow

The workflow connects sequencing strategy, bioinformatic interpretation, and development-facing reporting so the final output is usable by scientific, CMC, and business teams.

Intake and Study Design

Review strain history, existing WGS files, phenotype data, plasmid expectations, and intended development use.

Long-Read Sequencing

Generate or integrate PacBio, ONT, and short-read data according to genome complexity and accuracy needs.

Closure and Annotation

Assemble replicons, polish sequences, annotate ARG, VF, prophage, plasmid and MGE features with coordinate-level context.

Risk Interpretation

Prioritize findings by location, mobility markers, gene neighborhood, strain intended use, and follow-up evidence needs.

Report and Gap Map

Deliver a genome-level safety report and a practical checklist for preclinical data-package planning.

Published Data Supporting Long-Read Genome Closure for Resistome Risk Profiling

Chromosomal and plasmid genotyping map for GM Bacillus subtilis. (OA Literature) — Fig.1 Genotypic characterization of the GM *B. subtilis* 2014-3557. ^1,2

Berbers et al. demonstrated that combining short and long reads could reconstruct a circular chromosome and plasmid in a genetically modified Bacillus subtilis case study, while also locating multiple antimicrobial resistance determinants and plasmid-derived insertions that short-read assemblies had not resolved. The figure shows why genomic coordinates and replicon context matter: resistance-associated features, plasmid segments, and repeat-rich regions are interpreted differently when their physical arrangement is visible.

For LBP strain safety assessment, the study supports a practical principle: gene presence alone is not enough when ARGs, virulence-associated features, plasmids, or MGEs may affect mobility interpretation and development risk. Creative Biolabs can provide related long-read genome closure, resistome annotation, MGE profiling, and safety-report support to help teams convert closed-genome evidence into a clearer preclinical data package.

Why Creative Biolabs for LBP Genome Safety Profiling

We combine microbial genomics, live biotherapeutic development awareness, and practical safety-package framing so the output is more than a bioinformatics file set.

✓

Development-Facing Interpretation

We organize findings around decisions that matter to LBP teams, including strain continuation, licensor due diligence, safety testing, and CMC readiness planning.

✓

Integrated Genotype and Phenotype Logic

Genomic findings can be aligned with antimicrobial susceptibility testing, biological safety testing, and strain identity work to reduce contradictory package narratives.

✓

Flexible Sequencing Strategy

Depending on strain type and program needs, we can support long-read-only, hybrid, or comparative workflows for candidate selection and risk triage.

✓

Actionable Gap Mapping

Instead of stopping at feature lists, we identify follow-up assays, documentation needs, and data-package gaps that can be addressed before costly development commitments.

Recommended Services for Genome-Level LBP Safety Evaluation

These related Creative Biolabs services can extend genome risk profiling into strain identity confirmation, biological safety assessment, and phenotype-level antimicrobial susceptibility evidence.

Microbial Identification Solution for Industry Biological Safety Test for Live Biotherapeutic Products Antibiotic Susceptibility & Resistance Test for Live Biotherapeutic Products

Frequently Asked Questions

It is most useful after a candidate strain has been selected but before major preclinical package commitments, strain licensing, or partner diligence. It is also valuable when short-read WGS has detected ARG, VF, plasmid, prophage, or MGE signals without resolving their location.

Yes. Existing short-read data can be reviewed during intake and may be integrated into a hybrid assembly or used to compare earlier contig-level findings with long-read closure results.

ARG detection identifies candidate resistance genes. ARG risk profiling adds genomic location, neighboring mobile elements, plasmid context, transferability flags, phenotype alignment, and recommended follow-up tests so the finding can be interpreted in a development setting.

No. Genome closure improves interpretability, but safety conclusions should also consider strain identity, phenotype, susceptibility profile, intended route, manufacturing history, stability, and biological safety testing.

Helpful starting materials include strain taxonomy, source history, intended application, existing WGS files, plasmid expectations, antimicrobial susceptibility results if available, and any known genetic modifications or strain-banking records.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production

Live Biotherapeutics - Creative Biolabs - Video

References

Berbers, B., Saltykova, A., Garcia-Graells, C., et al. "Combining short and long read sequencing to characterize antimicrobial resistance genes on plasmids applied to an unauthorized genetically modified Bacillus." Scientific Reports 10, 4310 (2020). https://doi.org/10.1038/s41598-020-61158-0
Distributed under Open Access license CC BY 4.0, without modification.

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

ISO 9001 Certified - Creative Biolabs Quality Management System.

Tel:
Fax:
Email:
Global

Inquiry Basket